Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03367260 · ClinicalTrials.gov registry record
The Treatment Preferences of Women Diagnosed With Ovarian Cancer
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 115
- Enrollment target
NCT03367260: Completed study, sponsored by Duke University.
NCT03367260 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 115 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03367260 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 115 participants
- Enrollment target
Study Summary
The primary objective of this study is to apply best-practice stated-preference methods to quantify the extent to which women with ovarian cancer accept the risks, side effects, and out-of-pocket costs associated with treatment in return for progression-free survival benefit afforded by a treatment, regardless of whether there is an overall survival benefit.
Primary Outcome
In the DCE, women are asked to choose between two hypothetical treatment scenarios characterized using 7 attributes (treatment schedule, out of pocket cost, peripheral neuropathy, nausea and vomiting, fatigue, progression-free survival and overall survival).
Interventions
- OTHER Preference Elicitation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2017-10-19 |
| Est. Completion | 2019-01-04 |
What the finished NCT03367260 record still lists
NCT03367260 is an observational study that tracks outcomes without assigning an intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Preference Elicitation is the first listed.
NCT03367260 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03367260 about?
NCT03367260 is a clinical study titled "The Treatment Preferences of Women Diagnosed With Ovarian Cancer". The primary objective of this study is to apply best-practice stated-preference methods to quantify the extent to which women with ovarian cancer accept the risks, side effects, and out-of-pocket costs associated with treatment in return for progression-free survival benefit afforded by a treatment,...
What is the current status of trial NCT03367260?
This trial is currently completed. The enrollment target is 115 participants. The study started on 2017-10-19. Estimated completion is 2019-01-04.
What interventions are being tested in trial NCT03367260?
The interventions under investigation include: Preference Elicitation (OTHER).
Who is sponsoring clinical trial NCT03367260?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI